| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Vitruvia Medical AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.25 |
| 52 Week High | €1.35 |
| 52 Week Low | €0.20 |
| Beta | 2.99 |
| 11 Month Change | -16.67% |
| 3 Month Change | -50.00% |
| 1 Year Change | -51.92% |
| 33 Year Change | -98.49% |
| 5 Year Change | n/a |
| Change since IPO | -98.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 991 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | 1.1% |
| 1Y | -51.9% | -1.2% | 10.7% |
Return vs Industry: 991 underperformed the German Life Sciences industry which returned -1.5% over the past year.
Return vs Market: 991 underperformed the German Market which returned 7.6% over the past year.
Price Volatility
| 991 volatility | |
|---|---|
| 991 Average Weekly Movement | 9.9% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 991's share price has been volatile over the past 3 months.
Volatility Over Time: 991's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Claus Wiest | www.vitruvia-med.com |
Vitruvia Medical AG, a technology company, operates in the healthcare sector. The company supplies circular systems for medical devices primarily in robot-assisted surgery. It also focusses on the repair, production, and trading of medical devices and surgical instruments.
Vitruvia Medical AG Fundamentals Summary
| 991 fundamental statistics | |
|---|---|
| Market cap | €577.64k |
| Earnings (TTM) | -€535.43k |
| Revenue (TTM) | €1.76m |
0.3x
P/S Ratio-1.1x
P/E RatioIs 991 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 991 income statement (TTM) | |
|---|---|
| Revenue | €1.76m |
| Cost of Revenue | €458.49k |
| Gross Profit | €1.30m |
| Other Expenses | €1.83m |
| Earnings | -€535.43k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 73.92% |
| Net Profit Margin | -30.46% |
| Debt/Equity Ratio | -248.3% |
How did 991 perform over the long term?
See historical performance and comparison